Related Experiment Videos

Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells

B Wen1, E Deutsch, E Marangoni

  • 1Laboratoire UPRES EA No 27-10 Radiosensibilité-Radiocarcinogénèse Humaine and Unité METSI, Institut Gustave-Roussy, 94805 Villejuif Cédex, France.

British Journal of Cancer
|December 19, 2001
PubMed

Insights

Tyrphostin AG 1024, an insulin-like growth factor-1 (IGF-1) inhibitor, enhances cancer cell radiosensitivity and apoptosis. This IGF-1 inhibitor shows potential for combined therapy with irradiation in breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Insulin-like growth factor-1 (IGF-1) promotes tumor growth via PI3K/Akt signaling, inhibiting apoptosis and mediating mitogenesis.
  • IGF-1 receptor (IGF-1R) is a key mediator of IGF-1 actions in various cancers.

Purpose of the Study:

  • To investigate the effects of Tyrphostin AG 1024, a selective IGF-1R inhibitor, on MCF-7 human breast cancer cells.
  • To evaluate the impact of Tyrphostin AG 1024 on cell proliferation, radiosensitivity, and radiation-induced apoptosis.

Main Methods:

  • MCF-7 cells were treated with Tyrphostin AG 1024 and/or irradiation (4 Gy).
  • Cell proliferation, apoptosis, and protein expression (Western blot) were analyzed.
  • Key proteins investigated included phospho-Akt1, Bax, p53, p21, and bcl-2.

Main Results:

  • Tyrphostin AG 1024 inhibited proliferation and induced apoptosis in a time-dependent manner.
  • Combined treatment with Tyrphostin AG 1024 (IC20) and irradiation resulted in up to 50% growth inhibition.
  • Enhanced radiosensitivity and amplified radiation-induced apoptosis were observed with Tyrphostin AG 1024 treatment.
  • Molecular analysis revealed downregulation of phospho-Akt1 and bcl-2, and upregulation of Bax, p53, and p21, particularly with combined therapy.

Conclusions:

  • Tyrphostin AG 1024 significantly enhances the radiosensitivity and apoptotic response of breast cancer cells to ionizing radiation.
  • The observed effects are mediated through modulation of the PI3K/Akt pathway and apoptosis-related proteins.
  • Tyrphostin AG 1024 represents a promising therapeutic agent for combination with irradiation in breast cancer treatment.

Related Concept Videos